Philips v. Masimo: Federal Circuit Appeal Dismissed in Signal Processing Patent Dispute
What would you like to do next?
Choose your path based on your signal processing IP needs:
📋 Case Summary
| Case Name | Philips v. Masimo Corporation |
| Case Number | 22-1366 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Jan 2025 – Feb 2026 384 days |
| Outcome | Appeal Dismissed — Mutually Resolved |
| Patents at Issue | |
| Accused Products | Signal processing apparatus and method |
Case Overview
The Parties
⚖️ Plaintiff
Global technology leader with a substantial IP portfolio in healthcare technology, patient monitoring systems, and signal processing innovations.
🛡️ Defendant
California-based medical technology company renowned for its pulse oximetry and patient monitoring innovations, with an extensive IP portfolio.
Patents at Issue
This dispute involved four U.S. patents covering signal processing architectures and methodologies, foundational to physiological monitoring devices such as pulse oximeters and patient telemetry systems.
- • US5,632,272A — Signal processing apparatus
- • US6,263,222B1 — Signal processing apparatus
- • US6,699,194B1 — Signal processing apparatus
- • US7,215,984B2 — Signal processing apparatus and method
Developing signal processing technology?
Check if your product might infringe these or related patents before market launch.
The Appeal Dismissal & Analysis
Outcome
The Court of Appeals for the Federal Circuit dismissed the appeal pursuant to the parties’ joint stipulation of voluntary dismissal under FRAP 42(b). No damages award or injunctive relief was adjudicated at the appellate level. Each party was ordered to bear its own costs, signaling a mutually negotiated resolution.
Key Legal Issues
This dismissal means no precedential ruling emerged from this Federal Circuit appeal on the signal processing patents at issue. For practitioners monitoring CAFC jurisprudence, this case contributes no new claim construction guidance or infringement framework. However, the patents involved, particularly US5,632,272A and US7,215,984B2, represent technology generations that remained actively litigated into 2025-2026, underscoring their continued commercial relevance.
Filing a signal processing patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence. Trusted by law firms and technology teams worldwide.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in signal processing. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the signal processing space
- See which companies are most active in medical device patents
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Physiological signal processing architectures
Foundational Patents
Across multiple technology generations
Strategic Resolution
Dismissal implies negotiated settlement
✅ Key Takeaways
Voluntary Federal Circuit dismissals produce no precedential claim construction or infringement rulings.
Search related case law →Symmetric cost-bearing in joint dismissals frequently indicates negotiated licensing resolution; review related dockets.
Explore precedents →Philips’ sustained enforcement of 1990s-era signal processing patents illustrates the enduring value of foundational patent portfolios in healthcare technology.
Track Philips’ portfolio →The Philips-Masimo rivalry confirms that signal processing and medical device patents remain high-stakes litigation areas.
Analyze industry trends →Frequently Asked Questions
Four U.S. patents: US5,632,272A; US6,263,222B1; US6,699,194B1; and US7,215,984B2, all covering signal processing apparatus and methods.
The parties filed a joint stipulation of voluntary dismissal under FRAP 42(b), with each side bearing its own costs. No merits ruling was issued.
No precedential ruling emerged. However, the case confirms active enforcement of Philips’ foundational signal processing portfolio and signals the continued commercial significance of these patents in healthcare technology.
R&D teams developing signal processing or physiological monitoring technology should conduct freedom-to-operate (FTO) analysis against foundational Philips signal processing patents, even those approaching or past 20-year terms, particularly where continuation families may be active. Early engagement with patent counsel is crucial.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 2017-2587
- U.S. Patent and Trademark Office — Patent Full-Text Database
- World Intellectual Property Organization — Patent Cooperation Treaty (PCT)
- Cornell Legal Information Institute — Federal Rule of Appellate Procedure 42(b)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.